Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
about
Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic reviewClinical Phenotypes in Heart Failure With Preserved Ejection FractionPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal WomenDrug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.Phenotype-Specific Association of Single-Nucleotide Polymorphisms with Heart Failure and Preserved Ejection Fraction: a Genome-Wide Association Analysis of the Cardiovascular Health Study.Heart failure with preserved ejection fraction: a nephrologist-directed primer.Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.Einstein, the Blind Men, and the Elephant: Making Sense of Heart Failure With Preserved Ejection Fraction.Pericardial, But Not Hepatic, Fat by CT Is Associated With CV Outcomes and Structure: The Multi-Ethnic Study of Atherosclerosis.Reduced Myocardial Flow Reserve Is Associated With Diastolic Dysfunction and Decreased Left Atrial Strain in Patients With Normal Ejection Fraction and Epicardial Perfusion.Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis.A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort."Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis).Predicting heart failure: one size does not fit all.Publishing in a heart failure journal-where lies the scientific interest?Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.Reclassifying heart failure: time for disruptive innovation?Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?October 2016 at a glance: treatment of heart failure.
P2860
Q26779538-B75D91F2-BF3C-404A-A198-3E8ACD9DA482Q28073079-8856B9DF-ADF1-42EF-A455-0DF62D3DE5FCQ37058596-13303AB8-9639-4EE0-A7E8-5C4E48305ABDQ38387058-99F7C4ED-1304-4A2D-9969-6DE0B31E9354Q38638655-4C783230-761C-4BE9-82C9-6B4E614DACE3Q38756838-DC70EC3D-7A30-45C8-BBEE-A127CF458049Q39010896-FC2C55D6-CB2C-4748-9089-2906F26F0465Q39301622-BBDDC9E7-5EB7-4D12-A4F2-9F20498A7C1CQ41025346-02D1E431-D5E7-4123-B22F-3D428775EC77Q45947184-15B57004-3975-462E-BC1D-071E65DD911AQ46005004-7D9C66C2-DC68-470E-A6D4-6CB02D0FECFBQ46630081-BD5E62AE-5D8B-46F3-9D87-3D0C5B46AE77Q46694478-174A4540-DDC0-4848-A720-C6D43D271F69Q47734069-9A17D379-5D26-4F90-B7B6-1953D60B3E1DQ48055082-4A1775D4-3FE9-4B89-8D65-C6B867A2BEBFQ48310286-7B87DECB-FAB3-401D-AFDF-6FC8D70C4457Q48521572-CC67E50F-8762-44D5-9F35-71BD07B4A940Q49584550-29CFC71E-81A7-4618-9AB7-47AE53B7A4FFQ50044397-7AF801F9-BEC5-49AE-82FE-E3E03294DE2DQ50048467-87E0217C-8DF4-4A29-8C6C-BD3758C3987CQ50048824-AA0FD7D8-2C8F-4636-82FF-03D530A1AF92Q52627988-FE11BCAD-7FC5-4C83-BC53-9B1C90CB6D18Q53364388-59A63493-D33E-4130-AA01-BA2D41AF0D32Q54320351-BDC2CDF6-1954-411B-8591-41FCF77DE4E8Q54575009-F4DAA43E-47E7-4E3A-B5C0-70BF6BBD524C
P2860
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Characterization of subgroups ...... gnosis and treatment response.
@ast
Characterization of subgroups ...... gnosis and treatment response.
@en
type
label
Characterization of subgroups ...... gnosis and treatment response.
@ast
Characterization of subgroups ...... gnosis and treatment response.
@en
prefLabel
Characterization of subgroups ...... gnosis and treatment response.
@ast
Characterization of subgroups ...... gnosis and treatment response.
@en
P2093
P2860
P50
P356
P1476
Characterization of subgroups ...... gnosis and treatment response.
@en
P2093
Barry M Massie
James D Lewsey
JoAnn Lindenfeld
Michel Komajda
Peter E Carson
Robert S McKelvie
P2860
P304
P356
10.1002/EJHF.327
P577
2015-08-06T00:00:00Z